Unknown

Dataset Information

0

WJ-39, an Aldose Reductase Inhibitor, Ameliorates Renal Lesions in Diabetic Nephropathy by Activating Nrf2 Signaling.


ABSTRACT: Diabetic nephropathy (DN) is a chronic diabetic microvascular complication. Hyperactivity of the polyol pathway is involved in the pathogenesis of DN. Aldose reductase (AR), the rate-limiting enzyme of the polyol pathway, is expected to be an effective target in the treatment of DN. WJ-39 is a novel inhibitor of AR. The present study aimed at exploring the effects of WJ-39 in DN. DN was induced in rats by injecting 30?mg/kg streptozotocin (STZ). After 14 weeks, WJ-39 (10, 20, and 40?mg/kg) was intragastrically administered to the rats for 12 weeks. Treatment with WJ-39 significantly inhibited AR activation and ameliorated renal dysfunction and fibrosis in DN rats. WJ-39 reduced oxidative stress in the kidneys of DN rats by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. WJ-39 suppressed the activation of the nuclear factor-kappa B (NF-?B) pathway and the nucleotide-binding and oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome to reduce the secretion of inflammatory factors. Rat mesangial cells (RMCs) were cultured under hyperglycemic conditions. WJ-39 abrogated the high glucose- (HG-) induced, excessive production of reactive oxygen species (ROS) and inflammatory factors. However, transfection with Nrf2 small interfering RNA abolished the effects of WJ-39. WJ-39 also blocked the transforming growth factor-?1/Smad pathway to reduce the production of glomerular extracellular matrix proteins, ultimately reducing fibrogenesis in DN. Our results show that WJ-39 ameliorated renal injury in DN rats, and its effects on oxidative stress and inflammation were associated with the activation of Nrf2 signaling. Thus, WJ-39 and its mechanism of amelioration of renal lesions in DN rats by reducing renal inflammation, oxidative stress, and fibrosis injury could be an effective strategy for the treatment of DN.

SUBMITTER: Zhou X 

PROVIDER: S-EPMC7277034 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

WJ-39, an Aldose Reductase Inhibitor, Ameliorates Renal Lesions in Diabetic Nephropathy by Activating Nrf2 Signaling.

Zhou Xiaoyu X   Liu Zheng Z   Ying Ke K   Wang Huimin H   Liu Peng P   Ji Xuefei X   Chi Tianyan T   Zou Libo L   Wang Shaojie S   He Zhonggui Z  

Oxidative medicine and cellular longevity 20200530


Diabetic nephropathy (DN) is a chronic diabetic microvascular complication. Hyperactivity of the polyol pathway is involved in the pathogenesis of DN. Aldose reductase (AR), the rate-limiting enzyme of the polyol pathway, is expected to be an effective target in the treatment of DN. WJ-39 is a novel inhibitor of AR. The present study aimed at exploring the effects of WJ-39 in DN. DN was induced in rats by injecting 30 mg/kg streptozotocin (STZ). After 14 weeks, WJ-39 (10, 20, and 40 mg/kg) was i  ...[more]

Similar Datasets

| S-EPMC3071933 | biostudies-literature
| S-EPMC2909072 | biostudies-literature
| S-EPMC4335367 | biostudies-literature
| S-EPMC2831859 | biostudies-other
| S-EPMC1190371 | biostudies-literature
| S-EPMC6110315 | biostudies-literature
| S-EPMC10358522 | biostudies-literature
| S-EPMC3278231 | biostudies-literature
| S-EPMC8356418 | biostudies-literature
| S-EPMC5473486 | biostudies-literature